TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker
Erica L. Mayer(Harvard University), Eric P. Winer(University of Vermont), Rachel C. Jankowitz(University of Pennsylvania), Jennifer M. Specht(University of Washington), Antonio C. Wolff(Johns Hopkins University), Ian E. Krop(Yale Cancer Center), Kirsten M. Timms(Myriad (Germany)), Nadine Tung(Beth Israel Deaconess Medical Center), Lisa A. Carey(University of North Carolina at Chapel Hill), Vered Stearns(Johns Hopkins University), Charles M. Perou(University of North Carolina at Chapel Hill), P. Kelly Marcom(Duke University), Kathy D. Miller(Indiana University Health), Kathryn P. Componeschi(Dana-Farber Cancer Institute), Mothaffar F. Rimawi(Baylor College of Medicine), Lorenzo Trippa(Harvard University), Vandana G. Abramson(Vanderbilt University), Zhenying Tan‐Wasielewski(Dana-Farber Cancer Institute), Andrea L. Richardson(Johns Hopkins University), Carla I. Falkson, Tiffany A. Traina(Memorial Sloan Kettering Cancer Center)
Cited by 81
Related Papers
The Somatic Genomic Landscape of Glioblastoma
|Cell|2013|5.2k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
|Journal of Clinical Oncology|2010|4.3k